TRP-8803 BED trial to commence with Swinburne this quarter
Filed with ASX · · 4 pages · English
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Appendix 4D and Half Year Report for period 31 Dec 2024
- Positive interim results in Phase 2a TRP-8802 IBS trial
- Phase 1b extension results meet study objectives
- Phase 1b determines optimal parameters for TRP-8803 use
- $6m funding to fast track TRP-8803 clinical trial strategy
Later from Entropy Neurodynamics
- Binge Eating Disorder Trial receives Human Ethics approval
- Patient recruitment for world first TRP-8803 trial underway
- $2.6m in non-dilutive capital funding secured
- Landmark EEG Biomarker Agreement for Precision Psychiatry
- Appendix 4E and 2025 Annual Report
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics